Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D03BVW
|
|||
| Former ID |
DIB009848
|
|||
| Drug Name |
V-419
|
|||
| Synonyms |
Liquid hexavalent combination pediatric vaccine, Merck; HR-5-I (alternative liquid formulations), Merck; Alternative liquid formulation pediatric vaccine (diphtheria, tetanus, pertussis, polio, HBV, Hib), Merck; Diphtheria, tetanus, pertussis, polio, HBV, Haemophilus influenzae vaccine (alternative liquid formulations), Merck
Click to Show/Hide
|
|||
| Indication | Generalized anxiety disorder [ICD-11: 6B00; ICD-10: F41.1] | Phase 3 | [1] | |
| Poliovirus infection [ICD-11: 1C8Y] | Application submitted | [2] | ||
| Company |
Merck; sanofi pasteur
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01337167) Safety, Tolerability, and Immunogenicity of V419 Given Concomitantly With Prevnar 13 and RotaTeq (V419-005 AM4). U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.